新型抗血小板药物研究进展  

Research progress of new antiplatelet drugs

作　　者：杨颖[1] 蒋金法[1] 

机构地区：[1]同济大学附属同济医院心内科,上海200065

出　　处：《外科研究与新技术》2014年第4期263-266,共4页Surgical Research and New Technique

摘　　要：心脑血管血栓疾病是导致人类死亡的主要病因之一,而抗血小板治疗则是主要的治疗手段。阿司匹林与氯吡格雷是目前抗血小板治疗的标准组合,但两药合用导致的出血发生率增加、以及日益受到关注的阿司匹林和氯吡格雷抵抗,使得现有抗血小板治疗难以满足临床需要。文中就现有口服抗血小板药物治疗的局限性及一些新型抗血小板药物的研究进展作一综述。Thromboembolism disease of brain head blood-vessel is one of the major causes of death of human,and antiplatelet therapy is the main treatment. Aspirin and clopidogrel are the standard combination antiplatelet therapy,but the two fungicides have led to an increased incidence of bleeding,and are becoming more and more attended aspirin and clopidogrel resistance,which makes current antiplatelet therapy difficult to meet the clinical need. In this paper,the exisied limitations of oral antiplatelet medications and some new research progress in antiplatelet agents are summarized.

关 键 词：抗血小板药物 ADP受体拮抗剂 凝血酶受体抑制剂 5-羟色胺受体抑制剂 

分 类 号：R54[医药卫生—心血管疾病]